Use of calcipotriene cream (Dovonex® cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex®): A randomized, parallel-group clinical trial

American Journal of Clinical Dermatology

Volumn 7, Issue 3, 2006, Pages 177-184

  White, Stephen ^a   Vender, Ronald ^b   Thaçi, Diamant ^c   Haverkamp, Caroline ^d   Naeyaert, Jean Marie ^e   Foster, Richard ^f   Martinez Escribano, Jorge A ^g   Cambazard, Frédéric ^h   Bibby, Adrian ^f  

^a CLATTERBRIDGE HOSPITAL   (United Kingdom)

^b Dermatrials Research   (Canada)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d MARTINI HOSPITAL   (Netherlands)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f Leo Pharmaceuticals   (United Kingdom)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^h HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; TACLONEX;

ADULT; AGED; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN IRRITATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; CHI-SQUARE DISTRIBUTION; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS; TREATMENT OUTCOME;

EID: 33744920067     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200607030-00004     Document Type: Article

References (17)

1. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7
2. Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512-8
3. Guenther L, Cambazard F, van de Kerkhof PCM, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomised, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-23
4. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet™) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-93
5. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131-5
6. Ortonne JP, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004; 209: 308-13
7. Harrington CI, Goldin D, Lovell CR, et al. Comparative effects of two different calcipotriol (MC903) cream formulations versus placebo in psoriasis vulgaris. A randomised, double-blind, placebo-controlled, parallel group multi-centre study. J Eur Acad Dermatol Venereol 1996; 6: 152-8
8. Molin L, Cutler TP, Helander L, et al. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Br J Dermatol 1997; 136: 89-93
9. Halbaut L, Alcalde MT, Aróztegui M, et al. Relation between physicochemical characteristics and sensory properties in pharmaceutical preparations of topical application [in Spanish]. Cienc Pharm 1996; 6 (Pt 6): 289-96
10. Koo J, Gottlieb A, Lebwohl MG, et al. Topical psoriasis update: today's topical treatment strategies to optimize patient response and quality of life. Dermatol Times 2004 Jun; (Special Project): 1-11
11. Committee for Medicinal Products for Human Use, European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis [online]. Available from URL: http://www.emea.eu.int/ pdfs/human/ewp/245402en.pdf [Accessed 2006 Apr 26]
12. Barnes L, Altmeyer P, Forstrom L, et al. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 2000; 10: 199-204
13. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167-73
14. Cassano N, Miracapillo A, Coviello C, et al. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Invest 2006; 26: 227-33
15. Lebwohl M. Management of psoriasis with vitamin D used in combination with topical steroids [abstract no. 25]. International Congress on Clinical Dermatology 2000; 1996 May 28-31; Vancouver
16. Gordon KB, Feldman SR, Koo JYM, et al. Definitions of measures of effect duration for psoriasis treatments [editorial]. Arch Dermatol 2005; 141: 82-4
17. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-9